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ABSTRACT 
Autosomal Dominant Chronic Mucocutaneous Can- 
didiasis (AD-CMC) is characterized by defective T 
cell immunity, leading to fungal infections limited to 
mucosal surfaces. Recently it was discovered that 
mutations in the coiled-coil (CC) domain of STAT1 
are the cause of AD-CMC. STAT1 deficiency has 
been implicated in experimental models of oesopha- 
geal cancer (EC) and head and neck carcinoma 
(HNC). Both carcinoma types are prevalent among 
CMC patients. Consequently, we postulated that the 
same mutation in the STAT1 gene triggering AD- 
CMC, could also be involved in oesophageal or head 
and neck carcinogenesis. However we failed to iden- 
tify the c.820C>T mutation in the STAT1 CC domain 
in 3 cohorts of Dutch Caucasian origin: being 351 EC 
patients, 325 HNC patients and 309 controls. Al- 
though it seems valuable to investigate the relation- 
ship between AD-CMC and upper aerodigestive neo- 
plasms, the c.820C>T mutation in the STAT1 gene 
does not seem implicated in EC and HNC aetiology.  
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1. INTRODUCTION 
Signal transducers and activators of transcription (STAT) 
are dormant cytoplasmic proteins that upon activation 
regulate a wide variety of cellular processes, such as 
immune regulation, apoptosis, differentiation and prolife- 
ration [1,2]. In humans, seven STATs (1-4, 5a, 5b, 6) 
have been discovered [2]. Phosphorylation of tyrosine 
residues precedes activation of STAT and is achieved 
through two main signalling routes: the growth factor- 
and cytokine-signalling pathway [1,2]. Growth factor 
signalling occurs primarily via the Epidermal Growth 
Factor Receptor (EGFR). Conversely, cytokine activa- 
tion of Janus Tyrosine Kinases (JAKs), is an effective 
alternative STAT activation pathway.  
Dysregulation of these pathways is frequently ob- 
served in primary malignant tumours. Particularly STAT1 
and STAT3 play an important role in carcinogenesis, and 
both are well studied in a range of malignancies [3]. 
STAT1 target genes include tumour suppressor genes, 
whereas target genes of STAT3 are oncogenes that stimu- 
late cell cycle progression and inhibit apoptosis [3]. 
However, the exact role of STAT in oncogenesis remains 
complex and is incompletely understood. This is illus- 
trated by the fact that STAT1 and STAT3 are sometimes 
expressed simultaneously [3].  
STAT1 appears also to be involved in inflammatory 
and immunological diseases as it regulates immune ef- 
fector genes [4], and plays for example a causative role 
in chronic mucocutaneous candidiasis (CMC) [5]. CMC 
can be divided into several diseases: CMC with Auto- 
immune Polyendocrinopathy-Candidiasis-Ectodermal Dys- 
trophy (APECED), CMC without APECED but associ- 
ated with primary hypothyroidism, and sporadic CMC 
[6]. APECED has an autosomal recessive manner of in- 
heritance due to mutations in the AIRE gene, which ex- 
presses a protein that acts as a transcriptional activator 
[7]. The disease is characterized by the presence of 
autoreactive T lymphocyte responses, and subsequently 
neutralizing autoantibodies against cytokines of the Th17 
family such as IL-17 and IL-22 [7], leading to fungal 
infections (mainly Candida) limited to mucosal surfaces. 
The second syndrome is inherited through an autosomal 
dominant pattern. Recently it was discovered that muta- 
tions in the CC domain of STAT1 are the cause of auto- 
somal dominant CMC (AD-CMC) [5], resulting in de- 
fective type 1 and type 17 helper T cell immunity. The 
c.820C>T mutation in the STAT1 gene results in an ar- 
ginine to tryptophan amino acid substitution at codon 
274 [5] and leads to a defective CC domain of the STAT1 *Corresponding author. 
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protein. It has been shown that this defect results in de- 
fective IL-12R and IL-23R signalling pathways, with 
absent production of IL-17, IL-22 and IFNγ [5].  
STAT1 deficiency has been implicated in experimental 
models of oesophageal cancer (EC) and head and neck 
cancer (HNC) [8,9]. Both carcinoma types are prevalent 
among CMC patients [6,10]. Interestingly, Veerdonk et 
al. reported that 3 out of their 14 AD-CMC patients also 
suffered from EC or HNC [5].  
Consequently we postulated that the same mutation in 
the STAT1 gene, triggering AD-CMC as described by 
Veerdonk et al., could also be involved in oesophageal or 
head and neck carcinogenesis (Figure 1). 
2. MATERIALS AND METHODS 
Three cohorts of Dutch Caucasian origin were studied: 
351 patients with oesophageal cancer [11], 325 patients 
with head and neck carcinoma [12], and a group of 309 
healthy controls, recruited from the same geographical 
area as the patients [11]. A 60 bp region of exon 10 of 
the STAT1 gene, including the c.820C>T mutation, was 
examined by means of PCR followed by High Resolu- 
tion Melting analysis. After using the forward primer 3’- 
CTTGTGTCTTCCCAGGTTCA-5’, the reverse primer 
3’-CCAATTCCTCCAACTTTTTAAGC-5’ and EvaGreen 
(Biotium, Hayward, CA) as the fluorescent dye in the 
PCR, melting curves from 65˚C to 95˚C with a ramp rate 
of 0.1˚C/10 seconds were obtained with the CFX96TM 
Real-Time PCR Detection System (Biorad Laboratories, 
Hercules, CA). Melting curves were analyzed using the  
Precision Melt software (Biorad). Samples with deviant 
curves were sequenced. 
3. RESULTS AND DISCUSSION 
We failed to identify the c.820C>T mutation in the 
STAT1 CC domain in our two cohorts of 676 patients 
with upper aerodigestive cancer. Likewise, the mutation 
was also absent in 309 healthy controls. Demographics 
of patients and controls are shown in Table 1. 
It has been suggested that oral or oesophageal cancer 
in APECED-CMC may be induced by the production of 
carcinogens by C. albicans [13]. Although EC and HNC 
are reported in AD-CMC [5,6], a clear correlation has 
not been proven, and the possible mechanism remains 
unclear. However, as with APECED-CMC, prolonged 
exposure to C. albicans infections in the upper GI tract  
Table 1. Characteristics of patients with esophageal cancer, head 
and neck cancer and controls. 
Characteristics Patients  Controls 
 EC HNC  
Number (% of total) 351 (100%) 325 (100%) 309 (100%)


















Figure 1. Flowchart.   
c.820C>T c.820C>T
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can be an etiological factor [14]. IgA deficiency might be 
another immunological clarification for EC and HNC in 
AD-CMC. IgA deficiency, linked with neoplasm deve- 
lopment [14], has also been reported in APECED nega- 
tive CMC patients [14,15]. Although there is no known 
correlation with EC and HNC, IgA deficiency is reported 
to influence oesophageal dysplasia [16].  
Our findings do not support a role of the c.820C>T 
mutation in the STAT1 gene with oesophageal or head 
and neck carcinogenesis. The only mutation that was 
found twice in both patient groups and twice in the con- 
trol group, was the c.796G>A mutation (rs41473544). 
However, its occurrence in both patients and controls 
suggests no pathophysiological relevance.  
Furthermore, there is no other clear evidence that the 
STAT1 mutation is involved in EC risk, although there 
are reports that STAT1 activation induces apoptosis in 
EC cells in vitro [17,18], and loss of STAT1 activity was 
suggested to result in EC progression [8]. To our know- 
ledge no case-control or GWAS studies examining the 
role of STAT1 mutations in EC and HNC are known. For 
HNC as well, most of the STAT1 related basic research 
concentrates on biomarker and therapeutic potential [19, 
20].  
In conclusion, it seems valuable to investigate the pos- 
sible relationship between oesophageal and head and 
neck malignancy and APECED-CMC and AD-CMC. 
However, pursuing the c.820C>T mutation in the STAT1 
gene as an etiological factor for the development of 
EC/HNC in the absence of CMC does not seem worth-
while. Moreover, the STAT1 overexpression may not be 
independent, as STAT3 activation seems to occur simul-
taneously in a wide range of neoplasms. Consequently, 
adding the fact that STAT3 is an oncogene, haplotyping 
STAT1 and STAT3 genes in both carcinoma groups may 
be a more promising approach.  
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